Page 20 - HIV/AIDS Guidelines

Table 3. Laboratory Monitoring Schedule for Patients Prior to and After Initiation of
Antiretroviral Therapy

2–8 weeks
Entry Follow-up ART post-ART Every 3–6 Every 6 Every 12 Treatment Clinically
into before initiation or
care ART modification a initiation or months months months failure indicated
modification
CD4 count √ every 3–6 √ √ In clinically stable patients √ √
months with suppressed viral load,
CD4 count can be monitored
every 6–12 months
(see text)
Viral load √ every 3–6 √ √ b √ c √ √
months

Resistance √ √ d √ √
testing
HLA-B*5701 √
testing if considering
ABC
Tropism √ √ √
testing if considering a if considering a
CCR5 CCR5 antagonist
antagonist or for failure of
CCR5
antagonist-based
regimen
Hepatitis B √ √ √
serology e may repeat if
HBsAg (-) and
HBsAb (-) at
baseline
Basic √ every 6–12 √ √ √ √
chemistry f months
ALT, AST, T. √ every 6–12 √ √ √ √
bilirubin months
CBC with √ every 3–6 √ √ √ √
differential months if on ZDV
Fasting lipid √ if normal, √ √ √ √ √
profile annually consider 4–8 if abnormal at if normal at
weeks after last last
starting new measurement measurement
ART
Fasting √ if normal, √ √ √ √
glucose annually if abnormal at if normal at
last last
measurement measurement
Urinalysis g √ √ √ √ √
if on TDF h
Pregnancy √ √
test if starting EFV

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents C-2

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.